

Role of Antiepileptic Drugs in Cognitive and Behavioral Disorders in Patients with Autism Spectrum Disorders

Siniscalchi A^{1*}, Pezzella FR², Anticoli S², de Filippis R⁴, Gallelli L³

¹Department of Neurology, Annunziata Hospital, Italy

²Department of Emergency, San Camillo-Forlanini Hospital Rome, Italy

³Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Italy

⁴Istituto di Psicopatologia, Italy

Mini Review

Volume 1 Issue 1

Received Date: June 21, 2016

Published Date: July 04, 2016

***Corresponding author:** Antonio Siniscalchi, MD, Clinical Specialist, Department of Neurology, Annunziata Hospital via F. Migliori, 187100 - Cosenza, Italy Tel: 0039-0984-681351; Fax: 0039-0984-2163; Email: anto.siniscalchi@libero.it

Abstract

Autism spectrum disorders (ASDs) are a group of syndromes of diverse etiology with a common set of core symptoms that include three core symptoms: communication difficulties, social challenges and repetitive behavior. Drugs for treating these symptoms represent a huge area of unmet need, especially in pediatric population. Side effects affecting lipids and glucose metabolism and neurological status are among main concerns. Newer Antiepileptic drugs (AEDs) have improved side effect profiles and have shown some efficacy in subjects for treating aggressive symptoms in children with ASDs. In this review we examine and illustrate the mechanisms of action of AEDs; we speculate on the possible effect of new AEDs on pathophysiological mechanisms and on their clinical efficacy in cognitive and behavioral disorders of ASDs patients.

Keywords: Autism; Epilepsya; Treatment; Cognition

Abbreviations: ASDs: Autism Spectrum Disorders; AEDs: Antiepileptic Drugs; GABA: Gamma Aminobutyric Acid; NMDA: N-Methyl-D-Aspartate; DBPC: Double-Blind, placebo-Controlled; VPA: Valproate; PBO: Placebo

Introduction

Antiepileptic drugs (AEDs) represent a class of drugs with different pharmacology and chemistry sharing the common ability to decrease neuronal excitability; AEDs are mainly used to treat epilepsy, however, some of them

can be used for the treatment of neurological (i.e. migraine, neuropathic pain, hyperkinetic movements disorders) and psychiatric disease (i.e. anxiety bipolar disease, schizophrenia) [1-8]. Autism spectrum disorders (ASDs) are a group of syndromes of diverse etiology with a common set of core symptoms that include compromised social interaction, impaired communication, and repetitive behaviors [9,10]. ASDs can be idiopathic or co-morbid with other syndromes such as Fragile X or Rett syndrome. Notwithstanding the wide variation in the etiology, the consistency in symptomatology suggests that the mechanisms

underlying the pathology of ASDs are common. Growing evidence indicates that a possible mechanism could be impairment in the neuronal excitatory/inhibitory balance [10], as suggested by the high prevalence of epilepsy in patients with ASDs [11].

Although the atypical antipsychotics are very effective and commonly used in the treatment of pediatric aggression, there is concern about their prescription in the pediatric patients due to the incidence of side effects such as: metabolic abnormalities, diabetes mellitus, gain weight, insulin resistance, hyperlipidemia, neuroleptic malignant syndrome, dystonias and other extra-pyramidal reactions, including possible tardive dyskinesia [12,13].

Newer AEDs have improved side effect profiles and have shown some efficacy in subjects for treating aggressive symptoms. AEDs may represent a more tolerable long-term treatment for behavioral disorders in ASDs [13,14]. In addition, despite the efficacy of atypical anti-psychotics, there are patients who do not respond to monotherapy. A possible augmentation strategy can include combined treatment with an AED. The purpose of the present review is to relate the mechanisms of action of AEDs to pathophysiological mechanisms and clinical efficacy in cognitive and behavioral disorders in ASDs patients.

Mechanisms of action of Antiepileptic drugs

They can be classified into conventional and newer AEDs [7]. The first group encloses among others: acetazolamide, benzodiazepines, carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone and valproate, while the second comprises: eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, retigabine, tiagabine, topiramate, vigabatrin and zonisamide [5,7,15]. Although some AEDs act via more than one single mechanism of action (Table 1), they can also be classified according to the latter into three principal groups:

- 1) blockers of voltage-dependent sodium channels, so they reduce high-frequency repetitive firing in neurons (carbamazepine, oxcarbazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, topiramate, and valproate);
- 2) enhancers of GABA-mediated events (via the interaction with specific binding sites on the GABA-A receptor complex, the inhibition of GABA metabolism

or the reduction of its neuronal uptake): benzodiazepine, gabapentin, phenobarbital, tiagabine, topiramate, vigabatrin, valproate;

- 3) Blockers of voltage-gated calcium channels: ethosuximide and zonisamide [2,5,7].

An additional category of AEDs should also be considered according to new and specific mechanisms of action, such a category should comprise: drugs acting directly on excitatory glutamate neurotransmission blocking ionotropic glutamate NMDA (felbamate) and AMPA/kainate (phenobarbital, topiramate, perampanel) receptors [2,5,7]; levetiracetam which binds to synaptic vesicle protein 2A also inhibiting calcium release from intra-neuronal stores, opposing the activity of negative modulators of GABA- and glycine-gated currents, inhibiting excessive synchronized activity between neurons and inhibiting N-type calcium channels [7,16]; retigabine acting as a positive allosteric modulator of KCNQ2-5 (K(v) 7.2–7.5) ion channels [17]. Although the exact mechanisms of action of AEDs might not be considered completely clarified and the fact that newer AEDs do not seem to have an increased efficacy against drug refractory seizures, their use is supported by their overall better safety profile in comparison to traditional agents [7,18]. It has been reported that the new agents possess a better pharmacokinetic profile with a lower liver metabolism, fewer drug interactions and/or adverse effects, i.e. cognitive impairment, hepatotoxicity, biochemical as well as hematological alterations [5,19]. Current knowledge indicates that most of AEDs have more than one mechanism of action, contributing to their therapeutic efficacy and tolerability profile [7].

Clinical Use of AEDs in Cognitive and Behavioral Disorders in ASDs Patients

Conventional AEDs

Previous clinical studies reported that some conventional antiepileptic drugs are effectiveness in the treatment of behavioral and cognitive function in autism spectrum disorder (ASD). They are: valproate, carbamazepine and ethosuximide (Figure 1). Clinical studies reported effects of some AEDs in the behavioral and cognitive function for autism spectrum disorder (ASD). In randomized, prospective, double-blind, placebo-controlled (DBPC) studies, valproate monotherapy reduced repetitive behaviors [20] and irritability [21,22] in individuals with ASD. In a prospective double-blind, placebo-controlled study, 30 subjects (6-20 years of age) with pervasive developmental disorders and significant aggression were randomized and received treatment with

valproate (VPA) or placebo (PBO) for 8 weeks as outpatients. Mean VPA trough blood levels were 77.8 mcg/mL at week 8. Improvements in irritability, aggression, or general clinical status were not different between the valproate treated and placebo groups [23]. These results may be due by the fact that the majority of the children had a significant intellectual impairment; children were excluded if they had a previous positive response to valproate, and children were tapered off all other psychotropic and anti-epileptic medication just prior to entering the trial. Valproate has also been reported to improve behavioral and core ASD symptoms in a case series of ASD children with and without epilepsy [24] and to substantially improve ASD symptoms in case reports and series of children with subclinical epileptic-like discharges on EEG [13]. In a case series of children with ASD or ASD-like symptoms and epilepsy, Gilbert reported that 41% treated with valproate demonstrated positive psychotropic effects [25]. In a children with Landau-Kleffner Syndrome valproate a improvement in problematic behaviors, and language and social skills [26].

In a case series of children with ASD or ASD-like symptoms and epilepsy, Gilbert reported that 56% treated with carbamazepine demonstrated positive psychotropic effects, even if the evidence is limited to a single case-series [25]. In a retro-spective case-control survey study parents to be one of four AEDs that had the least detrimental effect on behavioral and cognition rated ethosuximide but there was no ratings of improvements in cognitive or behavioral symptoms [27].

In a case series of 66 children with epilepsy, 50 with ASD, and 16 with ASD-like symptoms, Gilbert reported a high prevalence of extremely negative behavioral adverse effects for clonazepam, phenytoin, phenobarbital, and nitrazepam [25] (Figure 1). Given that phenytoin, clonazepam, and phenobarbital were in the group of AEDs rated as having detrimental behavioral and cognitive effects on children with ASD in a retrospective case-control survey study [27]. These studies provide good evidence that valproate can have beneficial cognitive and behavioral effects in individual with ASD, while the others conventional AEDs reporting no significant improvements of these functions.

Newer AEDs

In a prospective, open-label trial levetiracetam improved attention, hyperactivity, emotional lability, and

aggressive behaviors in six drug-naïve boys but not in four boys who had been recently weaned off psychotropic medications [28]. However, no significant improvement or worsening of aberrant or repetitive behaviors or impulsivity or hyperactivity was found in a small prospective, randomized, DBPC trial of levetiracetam [29]. Thus, there is insufficient evidence to suggest that levetiracetam improves behavioral or cognitive features of ASD; however, these studies suggest that levetiracetam is well tolerated without detrimental cognitive or behavioral effects.

Lamotrigine did not improve or worsen aberrant or ASD behaviors in a small prospective, randomized, DBPC study [30] but in a case series (Level 4) of 50 children, 28% with ASD, parents reported improvements with lamotrigine in cognitive and ASD symptoms in 62% of children with ASD who had intractable epilepsy, even if seizure frequency did not improve [31]. Although lamotrigine may be cognitively enhancing in non-ASD epileptic individuals [32] and is efficacious for mood stabilization in bipolar disorder [33], there is insufficient evidence to suggest that it improves behavioral or cognitive features of ASD; rather these studies suggest that lamotrigine has few detrimental cognitive or behavioral effects in individuals with ASD.

In individuals with ASD, topiramate, when added on to risperidone, reduced irritability, stereotypical behavior, and hyperactivity in a DBPC study [34] but caused behavioral adverse effects in some participants in an open-label study [35]. Given the inconsistent results and the fact that topiramate can have neurocognitive adverse effects in individuals with epilepsy [36]. These studies regarding the use of newer AEDs showed that have not significant effects in the improvements of behavioral and cognitive functions. Also these studies suggest that levetiracetam is well tolerated without detrimental cognitive or behavioral effects, while lamotrigine has few detrimental cognitive or behavioral effects in individuals with ASD respect to topiramate (Figure 1).

In a clinical study the use of vigabatrin improved cognitive function in children with infantile spasms and with associated epilepsy and autism [37]. Also a improvement of cognitive function in children affected by tuberous sclerosis were observed [38]. So the use of vigabatrin can improve the cognitive function in patients with ASD (Figure 1).




Figure 1: Clinical use of AEDs.

Conclusion and Directions for Future Research

The primary indication for AEDs remains certainly epilepsy, even if other neurological conditions may be treated with these drugs when the typical treatments are ineffective. Several pathophysiological mechanisms inducing a neuronal excitability seems to be involved in an imbalance of both GABAergic and glutamatergic neurotransmissions and therefore could be similar in epilepsy and in cognitive and behavioral disorders ASDs. The main targets for the action of the

AEDs include enhancement of GABAergic inhibition, decreased glutamatergic excitation, modulation of voltage-gated sodium. In the treatment of cognitive and behavioral disorders in ASDs patients there is the

potential to use pharmacological agents with GABA-potentiating properties, and studies from animal models of ASDs indicate that a dysfunction in GABAergic signaling within particular neuronal circuits may account for most of the clinical symptoms found in autistic patients. In effect, post-mortem analysis on brain tissues from ASD patients as well as genetic and *in vivo* studies have largely contributed to unveil the impact of GABAergic signaling in these disorders [39]. GABA is involved in different cerebral processes [39]. At the beginning, GABA works as a trophic factor, modulating neuronal migration and maturation [40]. At later developmental stages, when synapses are formed, the release of GABA and glutamate, generate a primitive form of network-driven oscillatory events known as giant depolarizing potentials. γ -Aminobutyric acid is released from GABAergic cerebral interneurons. GABAergic interneurons not only exert a powerful control on network excitability but, in spite of

their relatively low number (10–15% of the entire neuronal population), are able to synchro- nize a large number of principal cells giving rise to coherent oscillations, which support different behavioral states of the animals and high cognitive tasks [41]. These observations point to GABA as one of the major players in the early assembly and formation of neuronal circuits in the developing brain. Therefore, it is not surprising that dysfunctions of GABAergic circuits have been implicated in various neuro-developmental and psychiatric disorders such as autism.

Several studies have shown that AEDs that acting on GABAergic synapses are able to ameliorate rescue behavioral deficits and to at least some of the symptoms observed in ASDs patients. Valproate that prevents degeneration and induces a regeneration of GABAergic interneurons [42] is effective in the improvement of cognitive and behavioral effects in individual with ASD. Also a treatment with vigabatrin, which blocks GABA catabolism by inhibiting GABA transaminase, is able to improve the autistic behavior of children affected by tuberous sclerosis [43]. AEDs with effects on decreasing glutamatergic neurotransmission on and/or voltage sodium or calcium channels may be also advantageous in non-epileptic conditions in ASDs patients. Clinical observation, however, suggests that compared with conventional AEDs, the newer AEDs are more tolerated and have less pharmacodynamic interactions [39, 5].

Research supporting the effectiveness of AEDs in cognitive and behavioral management in patients with ASDs is still inadequate and the limitations of existing research constitute substantial challenges in developing AED therapy recommendations for these disorders. So, more prospective clinical trials are necessary to confirm the efficacy of both conven- tional and newer AEDs in cognitive and behavioral disorderd in ASDs and determine better the proportion of responders in a larger group of patients.

In the future, a better understanding of the AEDs mechanisms of actions in cognitive and behavioral disorders in ASDs patients should be provided by increased knowledge of the underlying molecular deficits in these Fuctions in patients with AEDs disorders.

References

1. Carpay JA, Ferrari MD (2012) The adverse effects of antiepileptic drugs differ in patients with migraine. *Lancet Neurology* 11(11): 935.
2. Johannessen Landmark C (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. *CNS Drugs* 22(1): 27-47.
3. Siniscalchi A, Gallelli L, De Sarro G (2007) Drugs treatment of pain in multiple sclerosis. *Current Clinical Pharmacology* 2(3): 227-233.
4. Siniscalchi A, Gallelli L, De Sarro G (2010b) Use of antiepileptic drugs for hyperkinetic movement disorders. *Curr Neuropharmacol* 8(4): 359-366.
5. Siniscalchi A, Gallelli L, De Sarro G, Malferrari G, Santangelo E (2012a) Antiepileptic drugs for central post-stroke pain management. *Pharmacological Research* 65(2): 171-175.
6. Siniscalchi A, Gallelli L, Giofre C, De Sarro G (2012b) What's the role of topiramate in the management of patients with hyperkinetic movement disorders? *Pharmacological Reports* 64(1): 24-30.
7. Siniscalchi A, Gallelli L, Russo E, De Sarro G (2013) A review on antiepileptic drugs-dependent fatigue: Pathophysiological mechanisms and incidence. *European Journal of Pharmacology* 718: 10-16.
8. Zaremba PD, Bialek M, Blaszczyk B, Cioczek P, Czuczwar SJ (2006) Non-epilepsy uses of antiepilepsy drugs. *Pharmacological Reports* 58(1): 1-12.
9. Levy SE, Mandell DS, Schultz RT (2009) Autism. *Lancet* 374(9701): 1627-1638.
10. Pizzarelli R and Cherubini E (2011) Alterations of GABAergic signaling in autism spectrum disorders. *Neural Plasticity* 2011: 297153.
11. Brooks-Kayal A (2010) Epilepsy and autism spectrum disorders: are there common developmental mechanisms? *Brain Dev.* 32(9): 731-738.
12. Munshi KR, Oken T, Guild DJ, Trivedi HK, Wang BC, et al. (2010) The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders. *Pharmaceuticals* 3(9): 2986-3004.
13. Frye RE, Rossignol D, Casanova MF, Brown GL, Martin V, et al. (2013) A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. *Frontiers in Public Health* 13: 1-31.

14. Bachmann CJ, Manthey T, Kamp-Becker I, Glaeske G, Hoffmann F (2013) Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. *Res Dev Disabil* 34(9): 2551-2563.
15. Fattore C, Perucca E (2011) Novel medications for epilepsy. *Drugs* 71(16): 2151-2178.
16. Lyseng-Williamson KA (2011) Levetiracetam: a review of its use in epilepsy. *Drugs* 71(4): 489-514.
17. Gunthorpe MJ, Large CH, Sankar R (2012) The mechanism of action of retigabine (ezogabine), a first-in-class K_p channel opener for the treatment of epilepsy. *Epilepsia* 53(3): 412-424.
18. Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, et al. (2011) Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. *Epilepsia* 52(12): 2181-2191.
19. Johannessen Landmark C, Patsalos PN (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Rev Neurother* 10(1): 119-140.
20. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, et al. (2006) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. *Int J Neuropsychopharmacol* 9(2): 209-213.
21. Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, et al. (2006) Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. *J Clin Psychopharmacol* 26(4): 444-446.
22. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, et al. (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology* 35(4): 990-998.
23. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, et al. (2005) A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. *J Child Adolesc Psychopharmacol* 15(4): 682-692.
24. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S (2001) An open trial of divalproex sodium in autism spectrum disorders. *J Clin Psychiatry* 62(7): 530-534.
25. Gillberg C (1991) The treatment of epilepsy in autism. *J Autism Dev Disord* 21(1): 61-77.
26. Uğur C, Saday Duman N, Bektaş O, Kağan Gürkan C (2014) Antiepileptic treatment in a child with Landau Kleffner syndrome: a case report. *Turk Psikiyatri Derg* 25(4): 282-286.
27. Frye RE, Sreenivasula S, Adams JB (2011) Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey. *BMC Pediatr* 11: 37.
28. Rugino TA, Samscock TC (2002) Levetiracetam in autistic children: an open-label study. *J Dev Behav Pediatr* 23(4): 225-230.
29. Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, et al. (2006) Levetiracetam versus placebo in child- hood and adolescent autism: a double-blind placebo-controlled study. *Int Clin Psychopharmacol* 21(6): 363-367.
30. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW (2001) Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. *J Autism Dev Disord* 31(2): 175-181.
31. Placidi F, Marciani MG, Diomedi M, Scalise A, Pauri F, et al. (2000) Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. *Acta Neurol Scand* 102(2): 81-86.
32. Vajda FJ, Dodd S, Horgan D (2013) Lamotrigine in epilepsy, pregnancy and psychiatry – a drug for all seasons? *J Clin Neurosci* 20(1): 13-16.
33. Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, et al. (2010) Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 34(7): 1269-1272.
34. Canitano R (2005) Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. *Brain Dev* 27(3): 228-232.

35. Bootsma HP, Aldenkamp AP, Diepman L, Hulsman J, Lambrechts D, et al. (2006) The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. *Epilepsia* 47(Suppl 2): 24-27.
36. Askalan R, Mackay M, Brian J, Otsubo H, McDermott C, et al. (2003) Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. *J Child Neurol* 18(3): 165-170.
37. Jambaqué I, Chiron C, Dumas C, Mumford J, Dulac O (2000) Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. *Epilepsy Res* 38: 151-160.
38. Giada Cellot, Enrico Cherubini (2014) GABAergic signaling as therapeutic target for autism spectrum disorders. *Frontiers in pediatrics* 2: 70.
39. Behar TN, Schaffner AE, Scott CA, O'Connell C, Barker JL (1998) Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus. *J Neurosci* 18(16): 6378-6387.
40. Klausberger T, Somogyi P (2008) Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. *Science* 321(5885): 53-57.
41. Wei D, Yang F, Wang Y, Yang F, Wu C, et al. (2015) Degeneration and regeneration of GABAergic interneurons in the dentate gyrus of adult mice in experimental models of epilepsy. *CNS Neurosci Ther* 21(1): 52-60.
42. Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. *Br J Clin Pharmacol* 61(3): 246-255.